Costco Shares Gain Premarket After June Sales Jump 16.9%, Morgan Stanley Raises Price Target
Costco Wholesale Corporation (NASDAQ:COST) reported net sales of $18.92 billion for the retail month of June, a 16.9% growth year-on-year. The…
6 Top Precious Metal Stock Picks
On Thursday, Bank of America updated its precious metal price outlook and named its top precious metal stock picks for investors to buy heading into the second half of 2021.
Why JPMorgan Is Raising Tesla Delivery Estimates, EPS Estimates, Price Target
JPMorgan analysts increased several estimates for Tesla, Inc. (NASDAQ: TSLA) Wednesday following the automaker’s second-quarter vehicle delivery update.
Arrowhead’s Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.
Takeaways On Unity Biotech’s Clinical Data From A Bull Analyst
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX).
The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target.
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS).
The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target.
Why This ChemoCentryx Analyst Is Bullish
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan.
The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on shares of ChemoCentryx, Inc. with a $28 price target.
Why This Apple Stock Analyst Says It’s Time To Buy
After a not-so-enterprising first-half, Apple, Inc.
BofA Raises XPeng Target On P7, G3i, P5 Prospects
While Xpeng Inc - ADR (NYSE: XPEV) is facing strong demand for P7, the G3i launch scheduled for Friday could be the next catalyst, according to BofA Securities.
KeyBanc Raises Nvidia Price Target Signifying 16% Upside, Reiterates Overweight Rating
KeyBanc analyst John Vinh raised NVIDIA Corp’s (NASDAQ:NVDA) price target to $950 from $775. Vinh reiterated an Overweight rating. The new…